EMBC
Price
$12.75
Change
+$0.47 (+3.83%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
718.05M
134 days until earnings call
MYGN
Price
$6.20
Change
-$0.12 (-1.90%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
588.04M
85 days until earnings call
Interact to see
Advertisement

EMBC vs MYGN

Header iconEMBC vs MYGN Comparison
Open Charts EMBC vs MYGNBanner chart's image
Embecta
Price$12.75
Change+$0.47 (+3.83%)
Volume$34.83K
Capitalization718.05M
Myriad Genetics
Price$6.20
Change-$0.12 (-1.90%)
Volume$52.49K
Capitalization588.04M
EMBC vs MYGN Comparison Chart in %
Loading...
EMBC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EMBC vs. MYGN commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EMBC is a Buy and MYGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (EMBC: $12.28 vs. MYGN: $6.32)
Brand notoriety: EMBC and MYGN are both not notable
EMBC represents the Pharmaceuticals: Other, while MYGN is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EMBC: 310% vs. MYGN: 128%
Market capitalization -- EMBC: $745.1M vs. MYGN: $576.88M
EMBC [@Pharmaceuticals: Other] is valued at $745.1M. MYGN’s [@Medical Specialties] market capitalization is $576.88M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $169.15B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.79B. The average market capitalization across the [@Medical Specialties] industry is $9.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EMBC’s FA Score shows that 2 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • EMBC’s FA Score: 2 green, 3 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, EMBC is a better buy in the long-term than MYGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EMBC’s TA Score shows that 7 TA indicator(s) are bullish while MYGN’s TA Score has 5 bullish TA indicator(s).

  • EMBC’s TA Score: 7 bullish, 3 bearish.
  • MYGN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, EMBC is a better buy in the short-term than MYGN.

Price Growth

EMBC (@Pharmaceuticals: Other) experienced а +23.29% price change this week, while MYGN (@Medical Specialties) price change was +61.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.86%. For the same industry, the average monthly price growth was -3.35%, and the average quarterly price growth was +2.88%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +4.25%. For the same industry, the average monthly price growth was +1.87%, and the average quarterly price growth was -1.45%.

Reported Earning Dates

EMBC is expected to report earnings on Dec 23, 2025.

MYGN is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+1.86% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (+4.25% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EMBC($718M) has a higher market cap than MYGN($588M). EMBC YTD gains are higher at: -39.048 vs. MYGN (-53.902). EMBC has higher annual earnings (EBITDA): 207M vs. MYGN (-64M). EMBC has more cash in the bank: 209M vs. MYGN (91.8M). MYGN has less debt than EMBC: MYGN (158M) vs EMBC (1.55B). EMBC has higher revenues than MYGN: EMBC (1.08B) vs MYGN (831M).
EMBCMYGNEMBC / MYGN
Capitalization718M588M122%
EBITDA207M-64M-323%
Gain YTD-39.048-53.90272%
P/E Ratio8.65N/A-
Revenue1.08B831M130%
Total Cash209M91.8M228%
Total Debt1.55B158M982%
FUNDAMENTALS RATINGS
MYGN: Fundamental Ratings
MYGN
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
54
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EMBCMYGN
RSI
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
63%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
70%
Bearish Trend 4 days ago
76%
Momentum
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
67%
MACD
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 12 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
70%
Aroon
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
EMBC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRACX49.610.44
+0.89%
Putnam Research C
EFCAX22.510.15
+0.67%
Emerald Insights A
AVUAX16.310.07
+0.43%
American Century Mid Cap Value I
SFSNX17.62N/A
N/A
Schwab Fundamental US Small Company Idx
PFPPX10.88-0.11
-1.00%
Principal MidCap Growth R3

EMBC and

Correlation & Price change

A.I.dvisor indicates that over the last year, EMBC has been loosely correlated with NEOG. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if EMBC jumps, then NEOG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EMBC
1D Price
Change %
EMBC100%
+18.53%
NEOG - EMBC
37%
Loosely correlated
+1.60%
WAT - EMBC
37%
Loosely correlated
+1.15%
RVTY - EMBC
36%
Loosely correlated
+0.44%
MTD - EMBC
36%
Loosely correlated
+1.54%
BIO - EMBC
35%
Loosely correlated
-0.40%
More

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
+3.61%
WAT - MYGN
39%
Loosely correlated
+1.15%
GMED - MYGN
37%
Loosely correlated
+8.47%
EMBC - MYGN
33%
Poorly correlated
+18.53%
AORT - MYGN
31%
Poorly correlated
+25.23%
NEO - MYGN
30%
Poorly correlated
+0.69%
More